The global blockbuster oncology brands market size was valued at USD 47.2 billion in 2025 and is projected to grow from USD 51.0 billion in 2026 to USD 87.4 billion by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 38.0% in 2025. The rising prevalence of various cancer types across different age groups, coupled with ongoing advancements in oncology research, is driving market growth.
In addition, the expanding availability of innovative treatment approaches, including immunotherapies, targeted therapies, and cellular therapies, is providing patients with a broader range of therapeutic options, further supporting market expansion.
A blockbuster drug is a highly sought-after drug that generates annual sales of USD 1 billion or more for a pharmaceutical company. Regulatory bodies worldwide have accelerated approval rates for new drug therapies as first-line treatments. In addition, companies have invested heavily in research and development efforts for new drug formulations. These factors have collectively contributed to the high growth trajectory of the global market for blockbuster oncology brands.
In January 2026, according to the American Cancer Society (ACS) in its Cancer Statistics, an estimated 2.1 million new cancer cases and 0.6 million cancer deaths are expected to occur in the United States. The most common types of cancer, according to IARC, were lung and prostate cancer for men and breast cancer for women. Such a large and expanding patient population encourages pharmaceutical companies to accelerate the development of innovative oncology therapies. These new drug therapies come at a high cost to patients; however, favorable reimbursement policies are supporting the commercial success of blockbuster oncology brands and contributing to overall market growth.
Regulatory bodies worldwide, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others, have fast-tracked their approval rates for the application of innovative drug therapies in cancer treatment, such as targeted immunotherapy, CAR-T cell therapy, monoclonal antibodies, and many others. Tailored treatment approaches employed by oncologists, based on genetic and molecular profiling of tumors, further enhance treatment efficacy and drive market demand.
▪ Canada
▪ Mexico
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
▪ India
▪ China
▪ Australia
▪ South Korea
▪ Thailand
▪ Argentina
▪ Saudi Arabia
▪ UAE
▪ Kuwait
In addition, the expanding availability of innovative treatment approaches, including immunotherapies, targeted therapies, and cellular therapies, is providing patients with a broader range of therapeutic options, further supporting market expansion.
A blockbuster drug is a highly sought-after drug that generates annual sales of USD 1 billion or more for a pharmaceutical company. Regulatory bodies worldwide have accelerated approval rates for new drug therapies as first-line treatments. In addition, companies have invested heavily in research and development efforts for new drug formulations. These factors have collectively contributed to the high growth trajectory of the global market for blockbuster oncology brands.
In January 2026, according to the American Cancer Society (ACS) in its Cancer Statistics, an estimated 2.1 million new cancer cases and 0.6 million cancer deaths are expected to occur in the United States. The most common types of cancer, according to IARC, were lung and prostate cancer for men and breast cancer for women. Such a large and expanding patient population encourages pharmaceutical companies to accelerate the development of innovative oncology therapies. These new drug therapies come at a high cost to patients; however, favorable reimbursement policies are supporting the commercial success of blockbuster oncology brands and contributing to overall market growth.
Regulatory bodies worldwide, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others, have fast-tracked their approval rates for the application of innovative drug therapies in cancer treatment, such as targeted immunotherapy, CAR-T cell therapy, monoclonal antibodies, and many others. Tailored treatment approaches employed by oncologists, based on genetic and molecular profiling of tumors, further enhance treatment efficacy and drive market demand.
Global Blockbuster Oncology Brands Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, the analyst has segmented the global blockbuster oncology brands market report based on brands, treatment, distribution channel, and region:Brands Outlook (Revenue, USD Billion, 2021 - 2033)
- Opdivo
- Keytruda
- Perjeta
- Ibrance
- Tecentriq
- Gazyva
- Tagrisso
- Darzalex
- Zejula
- Revlimid
- Imbruvica
- Others
Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
- Lung cancer
- Breast cancer
- Multiple myeloma
- Lymphoma
- Others
Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Other
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
▪ Canada
▪ Mexico
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
- Asia Pacific
▪ India
▪ China
▪ Australia
▪ South Korea
▪ Thailand
- Latin America
▪ Argentina
- Middle East and Africa
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Blockbuster Oncology Brands Market Variables, Trends, & Scope
Chapter 4. Blockbuster Oncology Brands Market: Brands Estimates & Trend Analysis
Chapter 5. Blockbuster Oncology Brands Market: Treatment Estimates & Trend Analysis
Chapter 6. Blockbuster Oncology Brands Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Blockbuster Oncology Brands Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca PLC
- GSK plc
- Novartis AG
- Johnson & Johnson Services, Inc.
- AbbVie Inc.
- Amgen Inc.
